Abstract:The programmed death-1 receptor (PD-1) acts as a T-cell brake, and its interaction with ligand-1 (PD-L-1) interferes with signal transduction of the T-cell receptor. This leads to suppression of T-cell survival, proliferation, and activity in the tumor microenvironment resulting in compromised anticancer immunity. PD-1/PD-L-1 interaction blockade shown remarkable clinical success in various cancer immunotherapies. To date, most PD-1/PD-L-1 blockers approved for clinical use are monoclonal antibodies (mAbs); however, their therapeutic use are limited owing to poor clinical responses in a proportion of patients. mAbs also displayed low tumor penetration, steep production costs, and incidences of immune-related side effects. This strongly indicates the importance of developing novel inhibitors as cancer immunotherapeutic agents. Recently, advancements in the small molecule-based inhibitors (SMIs) that directly block the PD-1/PD-L-1 axis gained attention from the scientific community involved in cancer research. SMIs demonstrated certain advantages over mAbs, including longer half-lives, low cost, greater cell penetration, and possibility of oral administration. Currently, several SMIs are in development pipeline as potential therapeutics for cancer immunotherapy. To develop new SMIs, a wide range of structural scaffolds have been explored with excellent outcomes; biphenyl-based scaffolds are most studied. In this review, we analyzed the development of mAbs and SMIs targeting PD-1/PD-L-1 axis for cancer treatment. Altogether, the present review delves into the problems related to mAbs use and a detailed discussion on the development and current status of SMIs. This article may provide a comprehensive guide to medicinal chemists regarding the potential structural scaffolds required for PD-1/PD-L-1 interaction inhibition.

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

PD-1/PD-L1 Inhibitors for Immuno-oncology: from Antibodies to Small Molecules

From Monoclonal Antibodies to Small Molecules: the Development of Inhibitors Targeting the Pd-1/Pd-L1 Pathway

Small Molecules As PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy

Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics

Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Strategies for developing PD-1 inhibitors and future directions

Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules

Cancer Immunotherapy: An Overview on Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

Recent Advances In The Development Of Pd-L1 Modulators: Degraders, Downregulators, And Covalent Inhibitors

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion